Aspartate Transaminase (AST) Test

- Assesses AST levels, which can indicate liver or heart issues when elevated.

Aspartate aminotransferase (AST) is predominantly located within hepatocytes, myocardial tissues, skeletal musculature, the cerebral region, and the renal system. It serves as a nonspecific biomarker indicative of hepatocellular injury. AST, classified as an enzyme, is a protein that catalyzes specific biochemical reactions within the human organism. Its primary presence is noted in the hepatic tissue; however, it is also distributed in the cardiac, muscular, and various other biological tissues.[1] Typically, individuals exhibit low concentrations of AST in the bloodstream. In instances where hepatocytes or other AST-containing cells sustain damage, there is a release of AST into the circulatory system, which may result in elevated serum levels of this enzyme.[2]

Aspartate aminotransferase (AST, EC 2.6.1.1) manifests in human biological tissues as two distinct isoenzymes: one situated within the cytoplasm (c-AST) and the other within the mitochondria (m-AST). The primary sources of AST are striated muscle, myocardial tissue, and hepatic cells. An increasing volume of research indicates that the assessment of AST isoenzymes in human serum proves advantageous in evaluating the extent of damage to some of these organs. In the context of hepatic disorders, this diagnostic test is employed to evaluate liver necrosis and ascertain prognostic information.[3] Furthermore, it may aid in the identification of individuals suffering from active alcoholic liver disease. In cases of acute myocardial infarction, the quantification of AST isoenzymes yields diagnostic data that diverges from that acquired through the evaluation of total creatine kinase and lactate dehydrogenase, along with their respective isoenzymes.[4]

Liver function enzymes, specifically aspartate aminotransferase (AST) and alanine aminotransferase (ALT), exemplify emerging biomarkers associated with cardiovascular disease (CVD) risk. The ratio of AST to ALT has been demonstrated to correlate with the severity of various chronic hepatic disorders, encompassing both alcoholic and non-alcoholic liver diseases, autoimmune liver diseases, and hepatitis C.[5] Prior investigations have established that cardiovascular disease represents the principal cause of mortality in individuals with non-alcoholic fatty liver disease (NAFLD), with escalated rates of mortality correlating with increased liver-related fatalities over extended follow-up durations ranging from 10 to 20 years.[6] The detection and identification of hepatic disease within the community setting are considerably constrained. Liver disease frequently

remains asymptomatic until the advanced stages of cirrhosis manifest.[7,8] Nevertheless, employing the enzymes in a simplistic ratio (AST/ALT) or integrating them into composite panel marker tests has been demonstrated to possess diagnostic accuracy for significant liver pathology. Moreover, these indicators of liver injury enhance the prediction of forthcoming clinical events, including cardiovascular outcomes, in patients diagnosed with liver disease.[9,10] However, it remains uncertain whether the AST/ALT ratio can augment the prediction of cardiovascular outcomes in a generalized primary care demographic. These rudimentary hepatic markers are commonly accessible within primary care frameworks, presenting potential utility in risk prediction models grounded in primary care.

References

1. Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int 2007; 27:694–9. 10.1111/j.1478-3231.2007.01471.
2. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163:218–24. 10.1001/archinte.163.2.218
3. 10.Adams LA, Harmsen S, St Sauver JL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105:1567–73. 10.1038/ajg.2010.18
4. 11.Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113–21. 10.1053/j.gastro.2005.04.014
5. 12.Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865–73. 10.1002/hep.21327
6. 13.Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49:608–12. 10.1016/j.jhep.2008.06.018
7. 14.Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51:595–602. 10.1002/hep.23314
8. 15.Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846–54. 10.1002/hep.21496
9. 16.McPherson S, Stewart SF, Henderson E et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59:1265–9. 10.1136/gut.2010.216077
10. 17.Angulo P, Bugianesi E, Bjornsson ES et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145:782–9 e4. 10.1053/j.gastro.2013.06.057.